產(chǎn)品[
RKO 人結(jié)腸腺癌細(xì)胞
]資料
如果您對(duì)該產(chǎn)品感興趣的話(huà),可以
產(chǎn)品名稱(chēng):
RKO 人結(jié)腸腺癌細(xì)胞
產(chǎn)品型號(hào):
CRL-2577
產(chǎn)品廠(chǎng)商:
美國(guó)標(biāo)準(zhǔn)生物品收藏中心(ATCC)
產(chǎn)品文檔:
無(wú)相關(guān)文檔
簡(jiǎn)單介紹
CRL-2577 RKO 人結(jié)腸腺癌細(xì)胞,原代細(xì)胞|細(xì)胞系|細(xì)胞株|菌種;細(xì)胞庫(kù)管理規(guī)范,提供的細(xì)胞株背景清楚,提供參考文獻(xiàn)和培養(yǎng)條件!
RKO 人結(jié)腸腺癌細(xì)胞
的詳細(xì)介紹
CRL-2577 RKO 人結(jié)腸腺癌細(xì)胞
|
CRL-2577?
|
|
$329.00
|
|
RKO
|
|
MC Hollander, AJ Fornace
|
Biosafety Level:
|
1
|
|
frozen
|
|
See Propagation
|
|
adherent
|
|
Homo sapiens (human)
|
|
epithelial
|
|
Organ: colon
Disease: carcinoma
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
urokinase receptor (u-PAR) [51462]
|
|
Yes
|
|
p53 + (wild type)
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
|
|
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:12 is recommended
Medium Renewal: Every 2 to 3 days
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
|
|
culture medium 95%; DMSO, 5%
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003
recommended serum:ATCC 30-2020
derivative:ATCC CRL-2578
derivative:ATCC CRL-2579
|
|
51462: Boyd D, et al. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res. 48: 3112-3116, 1988. PubMed: 2835152
51463: Smith ML, et al. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene 10: 1053-1059, 1995. PubMed: 7700629
53329: Brattain MG, et al. Heterogeneity of human colon carcinoma. Cancer Metastasis Rev. 3: 177-191, 1984. PubMed: 6437669
53331: Bhat MK, et al. Tumor suppressor p53 is a negative regulator in thyroid hormone receptor signaling pathways. J. Biol. Chem. 272: 28989-28993, 1997. PubMed: 9360971
|
|